Targeting fibroblast growth factor receptor (FGFR) pathway in renal cell carcinoma

Francesco Massari, Chiara Ciccarese, Matteo Santoni, Antonio Lopez-Beltran, Marina Scarpelli, Rodolfo Montironi, Liang Cheng

Research output: Contribution to journalArticle

9 Scopus citations

Abstract

Fibroblast growth factor receptor (FGFR) pathway is involved in driving vascular endothelial growth factor (VEGF)-independent tumor angiogenesis, as a compensatory mechanism to escape VEGF-targeted therapies. Therefore, targeting FGF/FGFR axis seems to be a promising strategy in order to inhibit tumor angiogenesis and reduce resistance to VEGF receptor-tyrosine kinase inhibitors. This editorial is focused on the role of FGF/FGFR pathway in renal cell carcinoma and on the ongoing trials of emerging agents targeting this axis.

Original languageEnglish (US)
Pages (from-to)1367-1369
Number of pages3
JournalExpert Review of Anticancer Therapy
Volume15
Issue number12
DOIs
StatePublished - Dec 2 2015

Keywords

  • fibroblast growth factor receptor
  • kidney
  • personalized medicine
  • precision medicine
  • renal cell carcinoma
  • targeted therapy
  • vascular endothelial growth factor receptor

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Oncology

Fingerprint Dive into the research topics of 'Targeting fibroblast growth factor receptor (FGFR) pathway in renal cell carcinoma'. Together they form a unique fingerprint.

  • Cite this

    Massari, F., Ciccarese, C., Santoni, M., Lopez-Beltran, A., Scarpelli, M., Montironi, R., & Cheng, L. (2015). Targeting fibroblast growth factor receptor (FGFR) pathway in renal cell carcinoma. Expert Review of Anticancer Therapy, 15(12), 1367-1369. https://doi.org/10.1586/14737140.2015.1110488